full list rate price target
earn chang report pleas see
tabl page
 kick report octob follow abbott octob report
provid highlight compani upcom result updat model
reflect revis think end market corpor develop
hold heck ride far month
 month-to-d mtd-through healthcar
equip suppli index stat doesnt give justic
individu move within index doesnt reflect move smid
med-tech name sever med-tech stock said mani
beaten-up name still year quit handsom
what prompt weak view med-tech consid
rel safe maintain rel high multipl
investor demand safeti bump
think long-term fundament med-tech intact howev think
could bump ahead earn season there like
nois compani extra sell day though think look
underli perform manag team may need adjust forecast account
strengthen us dollar lastli sinc mani manag team
may start messag put take align expect rememb
bump bad could make opportun stock overcorrect
dont lose sight forest tree two bs
view investor concern question around boston
scientif upcom quarter organ sale acceler achiev full-
year organ sale growth guidanc think given recent wall worri game
throne fan think wall risk/reward seem favor particularli
long-term investor maintain overweight rate
think market believ constant currenc sale guidanc
howev mani investor like left confus manag commentari
investor confer septemb compani bottom-lin growth
prospect wont ep growth doubl digit decid
factor fx fx come believ underli fundament
compani solid maintain overweight rate
extra sell day quarter /vsi guidelin competit
heavili market telescop tct could problemat
high-margin high-growth product su patent
think risk/reward attract cross-countri investor meet
septemb left us feel reassur overweight rate
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
summari rate price target earn chang report chang shown bold
co
barclay research share price target price shown primari list currenc ep estim shown report currenc
current fiscal year estim barclay research fiscal year estim barclay research
question feel free reach us via bloomberg im email phone
result octob confer call et
result octob confer call et
result octob confer call et
result octob confer call et
result octob confer call et
result octob confer call et
result octob confer call et
result estimate octob confer call estimate et
fiscal result novemb confer call et
fiscal result novemb confer call et
result novemb confer call et
result estimate week confer call tbd
fiscal result novemb confer call et
 kick report octob follow abbott octob full calendar
compani confer call follow also highlight key item focu listen
compani upcom confer call
updat model reflect revis think end market
corpor develop updat model immateri
view model pleas follow link click compani name
pleas feel free reach via bloomberg instant messeng -- look kstew on-line
email call
week
schedul report
coverag barclay research inform compani provid inform purpos
invest recommend barclay research
note time daylight time
result octob confer call et
revenu ep actual estim
focu listen call
perform rel expect think js quarter like softer one
comment expect greatest impact biosimilar gener pharma busi
consum babi difficult comparison due prior year re-stock said
histor beat revenu driven pharma franchis js ep typic beat last
quarter big beat larg driven asp sale gain incom said
plan reinvest back busi higher opex beat like small
guidanc updat js current guidanc includ operational/const currenc growth
adjust acquisit divestitur js organ sale expect
increas report basi expect sale rang
billion note juli guidanc reflect averag euro guidanc slightli
current rate one variabl recent scrutin js result
incom line includ divestitur gain js guidanc includ billion
incom year assum tax rate adjust ep expect
includ fx headwind expect updat guidanc reflect currenc
rate movement expect rais guidanc perhap tighten rang
model year feel comfort given current fx rate
put take provid guidanc januari listen put take particularli
around incom commentari given elev level consensu
feel appropri time
liabil exposur share increasingli volatil news flow regard varieti
litig matter rang opioid talc risperd manag like reiter
stanc compani confid legal posit purs appeal look liabil
accrual special charg commentari may provid context around
timelin mileston matter
new product margin lever also think big focu call top-lin growth
prospect new product particularli within pharmaceut busi abil
ep surpris histori rel consensu
sale surpris histori rel consensu
barclay medic suppli devic
result octob confer call et
focu listen call
perform rel guidanc expect abbott expect organ sale growth
fx expect headwind divis oper abbott expect nutrit
mid-singl digit diagnost mid-to-high single-digit legaci diagnost high single-
digit rapid low-to-mid single-digit establish pharma mid-to-high singl digit
medic devic high single-digit adjust ep expect
guidanc updat abbott expect organ growth see fx headwind
expect adjust ep abbott like tighten ep rang
put take abbott provid annual guidanc along result call
ceo mile white comment manag team see top-lin growth rate fairli
sustain note compani target double-digit ep growth
libr sale libr us time world-wide libr sale total million y/i
constant currenc invest commun wait fda approv libr
state day manag note call file icgm
expect approv rel soon
alinity/diagnost manag expect alin long-term growth driver await
 approv alin molecular
structur heart compani like highlight mitraclip given growth recent posit
year coapt data tct well structur heart pipelin mitraclip sale
million y/i constant currenc also expect abbott updat
portico tavr us launch expect amulet laac us approv
ceo transit updat robert ford promot role chief oper offic octob
call ceo mile white comment ford expect key leadership
role compani long time read line comment
would provid timelin success
nutrit nutrit sale rebound past two year year slower trend listen
commentari sustain mid-singl digit growth
establish pharma emerg market sale growth remain high singl digit
sale flattish abbott exit third-parti distribut agreement
revenu ep actual estim
ep surpris histori rel consensu
sale surpris histori rel consensu
barclay medic suppli devic
result octob confer call et
focu listen call
revenu ep actual estim
organ revenu perform view lot skeptic organ sale
acceler organ growth boston scientif guidanc
includ benefit extra sell day full year manag
expect organ sale growth model growth low end guidanc
rang believ street expect growth also low end
manag cite anniversari acquisit like claret augmenix sell day benefit
watchman japan product launch across compani
guidanc updat scope data tct fuell pre-exist gener sale acceler
concern worri upcom aha trial data current guidanc organ sale
growth acquisit contribut includ btg fx
headwind million net/net result report sale growth ep
expect
aha data present concern recent concern market regard
ischemia trial american heart associ meet novemb evalu patient
stabl ischem heart diseas treat optim medic therapi coronari bypass
graft percutan coronari intervent stent expect manag provid
commentari view trial potenti exposur extent result favor
stent patient popul similar past studi like courag
put take boston typic provid forward year guidanc result boston
scientif provid long-rang plan june call organ revenu growth
annual period oper margin expans double-digit
adjust ep growth time btg acquisit close manag comment expect
btg acquisit accret ep current model adjust ep
product updat number new product pipelin across busi unit
highlight two believ import stock sentiment perspect
ep surpris histori rel consensu
sale surpris histori rel consensu
exalt single-us dispos duodenoscop year-end fda clearanc expect
timelin re-affirmed tct meet septemb
acur tavr tct manag re-affirmed expect ce mark european
approv us approv think like
barclay medic suppli devic
boston scientif total compani sale million organ growth
rhythm neuro sale million organ growth
cardiovascular sale million organ growth
medsurg sale million organ growth
result octob confer call et
focu listen call
guidanc edward expect sale billion adjust ep
manag comment typic slowest quarter due season
transcathet aortic replac valv tavr view expect tavr sale
high follow beat last quarter fda label expans low risk august
expect tavr sale million underli basi comparison ww
tavr sale million y/i underli basi ww tavr sale
million underli basi
sale billion underli growth top end rang tavr sale
billion underli sale growth top end rang tmtt sale
million structur heart sale million underli growth
critic sale includ casm top end million rang
underli growth fx expect million headwind sale
revenu ep actual estim
ep surpris histori rel consensu
transcathet mitral tricuspid therapi tmtt tmtt consid ew next growth
driver ew target million sale though think goal high
tmtt sale total million bring ytd total million impli signific
ramp sale expect gener pascal cardioband face suppli
challeng believ limit demand owe long procedur time expect updat
mitral tricuspid trial expect edward reaffirm commit sapien
pascal program believ cardioband could face redesign
surgic structur heart extent tavr sale see increas adopt intermedi
low risk patient surgic valv sale may pressur surgic structur heart sale
million underli basi reflect increas adopt premium
valu mix benefit expect updat harpoon mitral valv repair technolog
call edward comment european launch delay late due
slower regulatori environ
put take edward provid full-year guidanc investor confer
decemb though expect analyst gaug outlook ahead nevertheless
sale surpris histori rel consensu
figur
initi pivot
result octob confer call et
focu listen call
perform rel expect guidanc baxter expect oper constant
currenc growth us cyclo impact fx thu report sale growth
adjust ep expect includ impact
revaclear dialyz suppli disrupt
sale oper growth us cyclo competit impact fx headwind
report growth constant currenc basi renal includ
million headwind revaclear million in-cent hd bloodlin exit
medic deliveri low single-digit mid-singl digit
adjust cyclo clinic nutrit advanc surgeri high single-digit
acut therapi low-to-mid singl digit
put take baxter typic provid forward guidanc result though baxter
target establish lrp goal expect oper margin
rang year expect ep area
year
medic deliveri medic deliveri sale y/i constant currenc basi
bring ytd perform flat manag reiter target year
comp easier remain somewhat sceptic target
renal manag like provid updat revaclear expect impact
full year result million may provid updat potenti long-term benefit
kidney diseas execut order
pharmaceut resolut legaci clari facil warn letter remain risk factor
view could delay time new product launch
advanc surgeri floseal recomtrom benefit million due js
surgiflo suppli issu juli call baxter factor two month upsid though
restor suppli quarter bit sooner baxter factor
revenu ep actual estim
ep surpris histori rel consensu
sale surpris histori rel consensu
 updat septemb baxter announc acquisit cheetah medic hemodynam
monitor compani million cash front million mileston payment
deal expect close baxter expect deal immateri earn
barclay medic suppli devic
pharmaceut ex-fx growth adjust clari
clari acquisit recothrom preveleak barclay medic suppli devic
result octob confer call et
focu listen call
perform rel guidanc expect expect ep
reflect minim fx impact note full year one addit sell day
extra sell day help procedur busi manag note gener
impact perform capit busi addit expect progress
improv gross margin includ
guidanc updat expect organ sale growth rang
oper margin expans fx expect approxim neg
impact ep manag expect adjust ep reflect higher level sale
well tax rate trend toward low end initi guidanc
knee trend mako knee repres total compani sale recon
mako capit servic book perform account disproportion amount
investor focu us knee call manag note
see expect see materi impact robot competit zb rosa
nevertheless investor remain concern competit landscap place
robot global us total knee procedur exceed y/i
total mako procedur approxim
put take typic provid forward guidanc result expect
analyst call gaug manag view put take next year
updat anticip color continu integr stryker expect spine sale
growth acceler due cross-sel new instrument
mobiu septemb agre acquir mobiu imag sister compani
cardan robot million up-front cash plu million mileston payment
mobiu found focus integr advanc imag technolog medic
workflow airo truct scanner offer mobil real-tim imag cardan robot found
innov robot navig technolog system surgic
intervent radiolog procedur acquisit expect close
expect materi impact bottom line year
agreement octob announc licens agreement
patient-specif instrument psi use connect knee implant offer
includ triathlon total knee system
revenu ep actual estim
ep surpris histori rel consensu
sale surpris histori rel consensu
barclay medic suppli devic
result octob confer call et
focu listen call
perform rel expect provid quarterli guidanc
note extra sell day like caus report growth full-year growth
organ growth
guidanc updat expect full-year organ growth addit
compani expect million month contribut buffalo filter
fx headwind note result report revenu growth
million compani expect adjust gross margin improv adjust
sale adjust sg sale declin interest
expens million adjust effect tax rate
adjust ep expect grow
buffalo filter updat februari acquir buffalo filter lead manufactur
surgic smoke evacu technolog sinc deal close compani rais sale
expect buffalo filter million million buffalo filter revenu
total million march colorado becam second state pass surgic smoke
evacu legisl rhode island legisl pass june expect
updat front highlight call
revenu ep actual estim
ep surpris histori rel consensu
surgiquest updat januari acquir surgiquest airseal system
airseal system consist valve-fre trocar continu pressur sens integr
insuffl smoke evacu compani releas pediatr applic juli ad
exist thorac gener surgeri indic expect investor commentari focus
around sustain double-digit growth surgiquest busi
put take provid next fy guidanc report
result nevertheless expect focu put take especi relat
buffalo filter contribut compani long-term growth outlook manag
past comment see sustain mid-singl digit double-digit growth
compani said addit buffalo filter given recent success think investor
would like hear least mid-singl digit
new product number recent product launch product refresh
orthoped gener surgeri busi aao meet march compani launch
new platform shoulder hip extrem compani also introduc infin knee
platform may
sale surpris histori rel consensu
barclay medic suppli devic
februari acquir buffalo filter approxim million
buffalo filter lead manufactur surgic smoke evacu technolog
surgic smoke gener surgic procedur use
energy-bas devic cauter vessel vapor human tissu bodili
fluid smoke contain toxic chemic benzen toluen carbon
monoxid etc along aerosol pathogen small particl
absorb patient bodi laparoscop endoscop procedur
buffalo filter sale current -base would expect
leverag intern commerci infrastructur acceler buffalo filter
januari complet acquisit surgiquest million
surgiquest main product airseal system airseal system consist
valve-fre trocar continu pressur sens integr insuffl
smoke evacu use robot laparoscop procedur
airseal continu growth driver grow double-digit
result estimate octob confer call estimate et
focu listen call
perform rel expect specif guidanc quarter equal sell day y/i
urolift sale updat view share trade urolift sale perform
outlook primari driver behind sale growth acceler
expect urolift sale million constant currenc basi way comparison
urolift sale million also y/i constant currenc slightli
easier comp owe temporari suppli issu year ago million impact
full year manag expect urolift growth though note accrual
conting payment reflect higher rate growth call expect updat
urolift roll-out updat japan market opportun
guidanc updat constant currenc growth fx headwind report
sale growth adjust ep inclus fx headwind
 dollar strengthen past fx prompt ep revis
guidelin competit guidelin vsi largest product categori estim account
roughli million sale launch telescop guid extens cathet may
heavili promot product recent tct confer guidelin sale includ
teleflex intervent busi intervent sale constant currenc
basi monitor perform busi unit believ could
risk go forward owe competit landscap su patent
infring relat product
put take plan provid guidanc result februari
issu long-rang plan may cover year lrp includ organ
sale growth adjust gross oper margin
respect believ manag like reaffirm commit top-lin growth
investor meet septemb expect margin expans y/i
believ greatest expans like occur stage consid
invest spend fx rate lower end rang seem like us
pipelin repla call ez pla bla submiss target fda
ask addit test manag provid updat time
million assum lrp percuv laparoscop surgic system still limit
re-releas million assum lrp manta larg bore vascular closur limit
market releas manag see market market opportun
revenu ep actual estim
ep surpris histori rel consensu
sale surpris histori rel consensu
 outlook serial acquir manag state continu
look target expect compani comment landscap
barclay medic suppli devic
urolift sale million
anniversariesneotract vsi barclay medic suppli devic
fiscal result novemb confer call et
focu listen call
perform rel guidanc expect hillrom expect revenu increas
constant currenc basi flat report basi howev manag expect core
revenu growth includ contribut voalt fyivoalt contribut
well modest contribut breath ep expect
revenu ep actual estim
fiscal guidance/new lrp hillrom provid guidanc well issu new long-
rang plan last lrp call core sale growth
ep growth latter rais reflect impact tax reform
view given recent trend believ manag would like view current trend
achiev core growth would comfort wider sale
growth band take consider possibl less favor capit
equip spend environ futur believ ep growth probabl balanc
invest drive top line return investor surgic consum divestitur
dilut think one way frame ep outlook take year-end figur
guidanc reduc grow base
last year core sever move piec surgic consum
divestitur voalt breath acquisit think manag may guid
core growth includ acquisit voalt half year go
hillrom comment call expect breath contribut
expect manag target doubl digit ep growth view growth
target believ balanc invest acceler sale growth return
holder model ep
centrella updat centrella hillrom newer medsurg bed receiv lot focu
investor drive growth pp busi pp grew y/i core
basi us busi grow double-digit manag comment expect
centrella growth deceler face difficult comparison also expect
launch new medsurg bed sometim could add competit pressur
deal voalt contribut bit continu contribut
manag expect breath add think
manag continu look acceler sale growth
connect manag expect launch new subscription-bas offer part
advanc connect initi
ep surpris histori rel consensu
sale surpris histori rel consensu
growth think manag look anoth lever growth
barclay medic suppli devic
updat tax reform cumul
softwar compani million addit
million mileston payment
time acquisit manag note top-lin contribut
million annual expect double-digit growth
rate manag note account recognit requir
result revenu book
see full benefit revenu run-rat
voalt acquisit contribut littl
core revenu growth like contribut
bring contribut full year
would expect contribut bit
septemb hillrom acquir
breath technolog develop non-invas
ventil technolog peopl suffer respiratori failur
due copd disord accord manag
non-invas ventil market patient
breath current gener million annual revenu
hillrom believ product grow double-
digit manag believ leverag respiratori
channel particularli dme busi drive growth
august earn manag comment expect breath
contribut top-lin growth although
transact expect modestli dilut adjust ep
first year
fiscal result novemb confer call et
focu listen call
fiscal result rel expect expect becton sale growth fairli similar
perhap slightli slower given compani tough comp medic manag
solut year ago quarter
guidanc bd provid initi guidanc investor confer septemb
manag express confid abil grow sale constant currenc
messag around ep growth seem somewhat mix one investor confer note
could grow doubl digit absorb gore headwind tariff
fx anoth comment saw path double-digit ep growth note fx
variabl could come pressur would unwis cut much off-set
would agre reason think street/market expect may
somewhat mix whether becton manag wont guid double-digit ep growth
rate still model bare double-digit ep growth
bd intervent bd peripher intervent sale million y/i
compar constant currenc fxn basi busi pressur due
drug-coat balloon busi expect manag provid updat pma file
lutonix below-the-kne manag schedul call fda discuss file
addit data also expect updat perform newer product includ
wavelinq av fistula system venovo venou stent covera cover stent launch
medic manag systems/capex trend grow concern
hospit capit equip market trend sustain product becton
busi grow market gain share becton face difficult
comparison year ago compani benefit accler pump upgrad cycl
share gain pyxi despit becton manag believ still grow busi
quarter
china/emerg market emerg market led china highlight key sourc
growth manag expect doubl digit underli growth china expect
emerg market china focu well impact tariff
bd patch manag may provid updat patch program work
extern partner determin next-step program note pump
applic often discuss context diabet initi applic target
type diabet pump applic broader becton plan partnership
drug compani use drug deliveri applic
revenu ep actual estim
ep surpris histori rel consensu
sale surpris histori rel consensu
barclay medic suppli devic
result novemb confer call et
focu listen call
perform rel expect guidanc zb manag expect constant
currenc sale growth upper end wamgr note major bill
day headwind off-set quarter benefit manag expect
gross margin help fx hedg gain refund medic devic excis tax
guidanc updat manag expect report revenu flat fx
expect headwind dollar strengthen sinc last quarter
oper margin expect adjust tax rate expect
adjust ep
knee perform rosa updat total compani sale knee zb import
product line key focu invest commun zb lose share
number year mainli product gap well suppli constraint due
manufacturing/fda warn letter issu suppli constraint eas zb launch
persona revis system cementless knee limit launch rosa knee robot
system latter like attract attent call also expect focu
zb knee revenu growth trend constant currenc basi zb overal knee sale
y/i includ america emea apac fyi-stryk
record robot capit sale recon revenu though zb book knee revenu
compar knee revenu growth zb apples-to-appl
put take investor present septemb manag note expect
grow line wamgr manag also note expect see
pressur gross margin given price headwind absenc fx gain howev expect
see leverag sg yield slight improv oper margin line
believ ep growth like modest
warn letter august zb incur product delay henc suppli issu
connect remedi effort impact sale zb believ prepar fda re-
inspect facil time discret fda zb warn
letter outstand well
 believ manag like look portfolio manag enhanc overal
wamgr compani listen commentari
revenu ep actual estim
ep surpris histori rel consensu
sale surpris histori rel consensu
barclay medic suppli devic
result estimate week confer call tbd
revenu ep actual estim
focu listen call
perform rel expect avano comment expect organ sale growth
acceler estim organ sale
extent favor sell day could benefit result
system chang occur quarter would make variabl quarter
perspect model ep
reaction ropivacain suppli update/upd on-q fda drug shortag databas
updat show ropivacain suppli avail roughli month earlier
expect share react favor news believ
translat chang outlook believ significantli chang
trajectori compani said listen updat outlook on-q
recal last quarter manag announc sever action off-set headwind
see beyond drug suppli note disrupt shut-down drug filler
acquir summit medic product sell electron infus pump also enter
agreement bioq manufactur ready-to-us infus drug system still see
headwind on-q busi estim repres sale hospit
protocol shift drug therapi come market heron
ep surpris histori rel consensu
guidanc updat august manag reduc sale guidanc note ep
low end rang specif guidanc organ sale growth
inclus gamereadi neom acquisit summit expect constant
currenc sale growth adjust ep expect low end
put take expect guidanc along result compani lrp
target exit believ aggress includ organ sale growth exit
high singl digit gross margin ebitda margin
august call manag acknowledg achiev lrp would like push
coolief coolief highlight manag growth driver estim coolief
sale sale new code propos reimburs releas juli
knee though level reimburs disappoint listen commentari
manag effort work higher reimburs level
chronic compani like comment progress neom acquisit
growth focu compani
sale surpris histori rel consensu
barclay medic suppli devic
total compani sale growth adjust acquisit fx
pain manag sale growth adjust acquisit
histor provid medic devic segment barclay medic suppli devic
fiscal result novemb confer call et
focu listen call
fiscal result rel guidanc expect expect overal organ
growth similar rate divis expect cvg rtg sale growth
similar level respect mitg acceler
diabet deceler low singl digit growth fx expect headwind
manag expect modest improv oper margin off-set slight current
headwind ep expect rang
fiscal guidanc updat expect full-year organ sale growth guidanc
divis expect organ growth cvg mitg rtg
diabet expect grow lower end rang fx expect
headwind ep guidanc reflect compani debt
refinanc slightli lower tax rate ep continu includ fx headwind
revenu ep actual estim
fiscal guidanc expect organ growth expect acceler rel
order compani achiev full-year guidanc
leadership transit august unexpectedli announc geoff martha
current evp presid rtg take ceo effect next fiscal year april expect
commentari around select geoff well prioriti ceo oper
near-term pipelin updat manag note revenu growth acceler much
driven cadenc product launch across four segment believ manag
provid updat pipelin particularli regard product launch later fiscal year
mitg expect increment updat around timelin revenu contribut
surgic robot system reveal investor day hartford connecticut cvg
look forward commentari micra av pacemak reveal linq icm slate
late fiscal year rtg expect commentari around time interstim micro
interstim ii launch given recent pma file diabet expect time updat around
upcom minim launch
highlight broader product pipelin figur
ep surpris histori rel consensu
sale surpris histori rel consensu
barclay medic suppli devic
barclay medic suppli devic
continu cadenc new product plan speed-to-scal initi
interstim micro mri year-end
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight view share high-
qualiti growth asset believ compani
favor mix busi product
geograph perspect see medic devic
busi particularli diabet key driver
growth go forward believ growth profil
upsid case depend sever key factor
strong growth libr alin approv
adopt new product particularli within medic
devic abil drive margin expans
downsid case driven slower
libre/alin sale fx slowdown emerg
market inabl receiv product approv and/or
acquisit sentiment around likelihood
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
underweight believ compani
right strategi redeploy ip proce
medic devic growth initi howev
believ risk on-q franchis
coolief reimburs may pressur
earn leav compani short lrp
upsid case could driven greater sale
 lead improv outlook greater
recoveri on-q busi drug shortag eas
inabl achiev cost save
unsuccess intensifi drug shortag
could pressur on-q sale new pain
expect reset lower
believ appropri level near-
term ep growth significantli aid financi
engin share repurchas believ
warrant lower valuat multipl rel other
sector think risk/reward fairli
upsid case could driven gener
competit less expect greater
success bring new product market
greater-than-expect improv profit
accret
downsid case could driven greater-
pressur renal med deliveri fx rate
inabl drive pharma sale pharma price
inabl expand margin
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
co
overweight believ bd continu
success integr bard achiev plan
revenu cost synergi view recent
pullback share drug-coat balloon
concern overreact see upsid
share consid bd sale
ep growth profil compani view
valuat attract
upsid case could driven better-than-
bard acquisit improv overal
growth rate btk indic and/or favor
fda letter updat june panel
downsid case could driven foreign
exchang stronger usd could pressur
expect sale legaci bard busi
slowdown emerg market growth inabl
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight one
highest sustain sale growth profil larg cap
med-tech compani number new
product across busi segment
provid above-averag growth expect
double-digit ep growth continu believ
premium valuat warrant given
expect growth
upsid case could driven new product
regulatori approv time greater traction new
product improv profit success
integr leverag acquisit
downsid case could driven delay
inabl receiv regulatori approv slower
uptak new product greater competit
pressur key area stent structur
heart greater-than-expect price pressur
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight success
execut turnaround posit deliv
mid-single-digit sale double-digit ep growth
view acquisit buffalo filter posit
enhanc underli growth rate
upsid case could driven continu
success drive mid singl digit sale growth
continu strengthen us orthoped
improv new product contribut
greater expect
downsid case could driven slowdown
organ growth comp becom difficult
slowdown hospit capit equip market
invest spend drive futur growth
foreign exchang rate strengthen us dollar
higher tax
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
underweight believ sale growth like
slow edward face competit transcathet
aortic valv tavr expect limit leverag
edward invest transcathet mitral valv
tmvr/r opportun sale ep estim
street tmvr/r repres potenti
second act still risk like
upsid case may driven better-than-
expect tavr sale greater leverag
stronger uptak tmvr europ faster-
than-expect time tmvr/r product
downsid case may driven delay
inabl commerci tmvr/r technolog
slowdown tavr sale due market slowdown
and/or competit pressur fx rate
greater expens support tmvr/r
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight believ manag
right strategi chang portfolio mix
creat durabl mid singl digit sale doubl digit
ep growth profil compani worri street
consensu may bit high near-term
and/or addit invest may need
drive top-line rate ew
rate driven new product introduct better-
than-expect margin improv
downsid case driver includ challeng
hospit capital-expenditure environ inabl drive
acceler top-lin growth increas
competit pressur dilut
equal weight continu like jnj
continu innov bode well
longer term howev believ litig concern
like remain overhang stock along
concern regard near-term biosimilar
gener pressur also believ street
ep estim may high rate share equal
upsid driver includ capit deploy drive
faster growth greater success new drug
outcom greater margin expans
downsid risk includ drug price
pharmaceut pipelin lower expect
clinic commerci success medic devic
action drug/devic recal margin eros
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight believ
number new product across busi
allow sustain mid-single-digit growth
expect leverag provid
least high-single-digit ep growth believ
stock valuat still attract despit recent
appreci share
upsid case driver includ success
deploy market share gain key area
cardiovascular structur heart surgic
neurostimul greater margin expans
expect
inabl receiv product approv market
share loss key categori dilut deal
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight believ sustain
above-sector revenu growth profil see
multipl driver across three busi
believ deliv margin commit
goal least annual drive least
ep growth given outlook believ
premium pe justifi
growth greater success new product
greater success drive oper margin
downsid case driver includ slowdown
orthoped hospit capital-expenditure market increas
competit knee foreign exchang stronger
us dollar inabl drive margin expans
continu grow modestli deceler
success past deal notabl
neotract urolift vsi help acceler
overal growth believ sale growth
achiev warrant premium pe
stock current reflect equal weight
upsid case could driven greater urolift
vsi sale greater improv profit
improv core busi sale growth
rate accret
downsid case could driven slowdown
urolift sale rel expect challeng
within core busi foreign exchang rate
stronger us dollar higher interest rate
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight view appoint
bryan hanson ceo posit catalyst chang
believ orchestr turnaround
howev believ transform need
like take multipl year see prospect
signific sale margin expans
limit near-term
upsid case could driven improv
market trend orthoped greater success
improv price trend strateg
downsid case could driven inabl
receiv and/or execut new product approv
deterior price addit fda regulatori
exchang stronger us dollar dilut
valuat methodolog risk
valuat methodolog price target base ev/sal multipl appli multipl sale estim
arriv valuat med-tech compani substanti question growth outlook histor trade revenu
pt would equat ep
risk may imped achiev barclay research valuat price risk includ approv
abil compani sustain least mid-single-digit growth time uptak new product abil realiz cost save
target off-set strand cost chang effect tax rate foreign exchang success deploy capit dilut
valuat methodolog set price target primarili reli forward price-to-earnings methodolog pt appli target pe
ep estim
risk may imped achiev barclay research valuat price new product import baxter
growth outlook therefor approv uptak new product key risk factor gener competit particularli cyclo
brevibloc could pressur earn and/or extent pressur less expect favor impact fx rate stronger us dollar
could also pressur baxter sale earn outlook risk includ signific reimburs chang fda govern
co
valuat methodolog set price target primarili reli forward price-to-earnings methodolog price target appli
multipl calendar ep
risk may imped achiev barclay research valuat price upsid risk factor extent becton
success integr bard see greater expect revenue/cost synergi downsid fx stronger us dollar commod
cost could greater headwind risk factor includ time success new product increas competit key product
drug-coat balloon infus pump signific chang reimburs fda govern action
valuat methodolog valu share use price-to-earnings methodolog price target appli target pe
ep level similar stock current trade ep compar high growth larg cap med-tech
risk may imped achiev barclay research valuat price key risk upsid downsid
relat trajectori sale growth new product integr upsid risk includ greater success new product
healthcar reform litig outcom inabl drive margin expans inabl integr acquisit govern action
valuat methodolog set price target primarili reli forward price-to-earnings methodolog believ multipl ew
share like compress given potenti slower growth part due greater competit transcathet aortic valv market
believ transcathet mitral tricuspid opportun may take take play price target appli pe multipl
ep estim
risk may imped achiev barclay research valuat price greater transcathet aortic valv
replac tavr sale success transcathet mitral tricuspid therapi tmtt could result higher earn expand pe
risk factor includ new product approv particularli mitral valv competit product launch signific chang
reimburs product failur valv thrombosi advers long-term outcom may chang usag trend product patent
litig outcom fda govern action
valuat methodolog set price target primarili reli forward price-to-earnings methodolog price target appli
price-to-earnings multipl calendar ep
risk may imped achiev barclay research valuat price upsid new product drive acceler
sale ep growth accret acquisit continu favor hospit capital-expenditure environ downsid less favor trend
hospit capital-expenditure slower uptak new product strengthen us dollar higher tax rate risk includ signific reimburs
chang fda product approv time competit pressur fda govern action
valuat methodolog set price target primarili reli forward price-to-earnings methodolog price target appli pe
multipl ep estim
risk may imped achiev barclay research valuat price fx rate recent acquisit could
pressur earn growth competit pressur particularli area knee competitor launch compet robotic-assist
system could impact growth outlook sentiment toward stock time ultim receipt new product approv could
affect outlook risk includ signific chang reimburs potenti dilut associ acquisit product failur
fda govern action
valuat methodolog risk
valuat methodolog set price target primarili reli forward price-to-earnings methodolog price target appli pe
multipl ep estim premium market other med-tech sector believ
warrant given higher growth rate
risk may imped achiev barclay research valuat price upsid extent neotract urolift sale
higher expect could drive upsid sale earn lead higher pe downsid urolift sale disappoint core
growth fail improv fx stronger us dollar higher interest rate half debt float risk includ time receipt
new product approv competit pressur particularli key product like urolift signific chang reimburs fda
govern action
valuat methodolog set price target primarili reli forward price-to-earnings methodolog appli multipl
adjust cash ep estim sinc zmh/zbh share trade average pe multipl high low
equat discount given compani growth profil believ discount med-tech sector
warrant multipl closer histor rel pe averag appropri
risk may imped achiev barclay research valuat price upsid resolut fda matter
acceler top line growth improv margin profil downsid delay new product approv failur see signific
increas new product uptak neg earn revis addit cost associ on-going manufactur issu risk factor
includ signific reimburs chang competit pressur dilut associ potenti acquisit integr acquir
busi proce sale busi fda govern action
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
